Fasting reduces tear production

Article

Fasting significantly reduces the amount of tears produced by the eye and increases the osmolarity of the tears, according to new research.

Fasting significantly reduces the amount of tears produced by the eye and increases the osmolarity of the tears, according to new research published in Eye & Contact Lens: Science & Clinical Practice. Fasting does not deteriorate the parameters of corneal topography or ocular aberrations in people who are healthy, however.

The study authors conducted a prospective controlled study of 29 eyes in 29 healthy men (mean age, 27.8 ± 5.9 years; range, 20 to 47 years). All of the men underwent corneal topography via a placido disc corneal topography and aberrometry device (OPD-Scan II, Nidek) before their ophthalmic examinations. Researchers used an osmometer (OcuSense, Tear Lab) to measure tear osmolarity. They also evaluated ocular surface disease index (OSDI) scores, tear break-up time (BUT), Schirmer I test and lissamine green staining.

The investigators took measurements between 4 pm and 5 pm before and during Ramadan and compared them using paired sample t test, considering a P value of less than 0.05 as statistically significant.

The researchers found:

  • The mean tear osmolarity values were 285.6 ± 8.2 mOsm/L in nonfasting periods and 293.3 ± 16.0 mOsm/L in fasting periods.
  • The mean Schirmer I values were 14.8 ± 6.0 mm in nonfasting periods and 10.6 ± 5.3 mm in fasting periods.
  • Tear osmolarity, OSDI and Oxford grading scores significantly increased during the fasting period compared with the nonfasting period.
  • Schirmer I values and IOP decreased during the fasting period compared with the nonfasting period.
  • No significant differences occurred in tear BUT, keratometry values and corneal aberration measurements in nonfasting periods compared with fasting periods.

To read an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.